A Clinical Pharmacology Study of the Novel, Selective Urate Reabsorption Inhibitor Dotinurad in Outpatients

Clinical and Experimental Nephrology - Japan
doi 10.1007/s10157-020-01857-0
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Clinical Efficacy and Safety of Dotinurad, a Novel Selective Urate Reabsorption Inhibitor, in Japanese Hyperuricemic Patients With or Without Gout: Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Confirmatory Phase 2 Study

Clinical and Experimental Nephrology
PhysiologyNephrology
2019English

Pre-Clinical Pharmacology of AZD3965, a Selective Inhibitor of McT1: DLBCL, NHL and Burkitt’s Lymphoma Anti-Tumor Activity

Oncotarget
Oncology
2017English

A Selective FLT3 Inhibitor Shows Clinical Efficacy in AML

Cancer Discovery
Oncology
2013English

Functional Characterization of Urate Transport via a Novel Urate Efflux Transporter URATv1.

GOUT AND NUCLEIC ACID METABOLISM
2009English

Pharmacokinetics, Pharmacodynamics, and Tolerability of Verinurad, a Selective Uric Acid Reabsorption Inhibitor, in Healthy Japanese and Non-Asian Male Subjects

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2018English

CGX1037 Is a Novel PKC Isoform Delta Selective Inhibitor in Platelets

Platelets
MedicineHematology
2014English

Pharmacology of a Phosphorus-Containing Novel Angiotensin Converting Enzyme Inhibitor, SQ29 852 in Anhesthetized Dogs.

Journal of Pharmacobio-Dynamics
1991English

First‐in‐human Phase I Study of E7090, a Novel Selective FGFR Inhibitor, in Patients With Advanced Solid Tumors

Cancer Science
Cancer ResearchMedicineOncology
2020English

A First in Human Study of the Selective Cardiac Myosin Inhibitor, CK-3773274

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy